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Adipocytes disrupt the translational programme of
acute lymphoblastic leukaemia to favour tumour
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The specific niche adaptations that facilitate primary disease and Acute Lymphoblastic
Leukaemia (ALL) survival after induction chemotherapy remain unclear. Here, we show that
Bone Marrow (BM) adipocytes dynamically evolve during ALL pathogenesis and therapy,
transitioning from cellular depletion in the primary leukaemia niche to a fully reconstituted
state upon remission induction. Functionally, adipocyte niches elicit a fate switch in ALL cells
towards slow-proliferation and cellular quiescence, highlighting the critical contribution of the
adipocyte dynamic to disease establishment and chemotherapy resistance. Mechanistically,
adipocyte niche interaction targets posttranscriptional networks and suppresses protein
biosynthesis in ALL cells. Treatment with general control nonderepressible 2 inhibitor
(GCN2ib) alleviates adipocyte-mediated translational repression and rescues ALL cell
quiescence thereby significantly reducing the cytoprotective effect of adipocytes against
chemotherapy and other extrinsic stressors. These data establish how adipocyte driven
restrictions of the ALL proteome benefit ALL tumours, preventing their elimination, and
suggest ways to manipulate adipocyte-mediated ALL resistance.
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Despite remarkable improvements in the treatment ofpaediatric ALL with cure attainable for the majority(>80%) of patients1, more than half of adults with ALL
will relapse and die within 5 years of diagnosis despite achieving
an excellent initial response to treatment2. These results indicate
that whilst current treatments are effective at eradicating the bulk
of the adult ALL tumour, complete disease eradication in these
patients is rare and individuals remain at risk of disease recur-
rence. Thus, a central quest in adult ALL is to define the critical
drivers of leukaemia cell persistence as a key strategy for over-
coming eventual therapy failure. Clinically, the therapy-surviving
leukaemia is characterized as the minimal residual disease
(MRD), which strongly and independently predicts a high sub-
sequent risk of disease recurrence3–5, emphasizing the key
importance of these targets to ALL evolution. Hallmarks of
therapy-latent MRD subclones include intrinsic chemoresistance,
dormancy and long-term persistence as well as functional plas-
ticity, as assessed experimentally6,7 and predicted clinically.
However, the regulatory mechanisms underpinning these aber-
rant states are not completely understood. Of relevance here is the
increasing understanding of the broad biological context of MRD
subclone escape beyond that predicted by genotype and epige-
netics alone8,9, raising interest in nongenetic drivers of this
process10. The relevant player here is the bone marrow micro-
environment (BMM), the primary residence of ALL; comprising a
highly diverse network of cellular (mesenchymal stroma, osteo-
blasts and endothelial cells), soluble and structural factors that
work together to coordinate and maintain haematopoietic stem
cell (HSC) function11. To perform its role, the BMM must adapt
to changing physiological contexts while still regulating and
maintaining HSCs, emphasizing the principle that BMMs are
inherently dynamic12. This distinct property of the BM niche is
co-opted by leukaemia cells to support developing tumours and
to shaping the ecological competition between leukaemia and
healthy haematopoiesis, a process driven by aberrant crosstalk
between leukaemia cells and BM stroma13–17. Upon exposure to
chemotherapeutic stress, BMMs undergo further
adaptation12,18,19, highlighting the continuously evolving habitat
in which leukaemia cells reside. These findings indicate that
niches in the BMM may differ dynamically during primary dis-
ease and after chemotherapy treatment18,19. However, many
studies fail to account for these niche dynamics explicitly and
from the outset. Moreover, the appropriate context for MRD
(<5% leukaemia blasts) is defined after the transition to mor-
phological remission, yet the niche in this setting has yet to be
fully defined. Where this paradigm has been applied, emergent
and novel mechanisms of niche-resistance have been
identified14,20, highlighting the fundamental importance of tem-
poral dynamics in determining which events precipitate treat-
ment failure.
We therefore hypothesized that the evolving course of BM
niches from ALL disease through to remission-inducing che-
motherapy would provide a tool for mapping dynamic para-
meters that temporally and biologically contribute to subclone-
specific resistance. Here we show that the transition from disease
to treatment and remission rebuilds the adipocytic BM niche, a
major BMM implicated in ALL resistance, and demonstrate a
previously unknown capacity of adipocytes to non-cell autono-
mously repress the ALL proteome as a mechanism for increasing
ALL cell quiescence and multistress resistance that may ulti-
mately contribute to leukaemia re-evolution.
Results
The adipocyte BM niche is dynamically remodelled during ALL
pathogenesis and treatment. To probe the transitional nature of
BMM, we compared the composition of matched BM biopsies
taken at initial ALL diagnosis and after remission induction by
gross histology in eight adult ALL patients. Our studies were
limited to B lineage ALL (B-ALL), which accounts for >80% of
the disease incidence21. Consistent with the assertion of niche
evolution, we observed profound remodelling of the BMM
accompanying ALL development and again after therapeutic
intervention, most strikingly affecting adipocyte compartments,
which were profoundly depleted in ALL-BMs compared to
healthy controls, with apparent adipocyte reconstitution upon
remission attainment (Fig. 1a). Adipocytes are microenviron-
mental cell types that have a well established role in ALL
resistance14,17,19,22–27; however, the niche dynamics leading to
this stage have been minimally explored, prompting us to
investigate these BM components further. We first applied cus-
tom image analysis to rigorously define and quantify the temporal
changes in BM adipocyte stucture. These assessments revealed
a profound loss of adipocyte numbers (Fig. 1b) as well as major
reductions in adipocyte size (Fig. 1c) at ALL diagnosis, impli-
cating both of these factors in the profound adipocyte suppres-
sion observed under this condition. In contrast, remission
biopsies demonstrated an evolution to normal adipocyte numbers
(Fig. 1b), indicating a return of adipocyte population home-
ostasis upon successful therapy. These outcomes differ from those
reported in AML, where chemotherapy leads to an inhibition of
adipogenesis in the BM28. Notably, remission states did not fully
normalize adipocyte size (Fig.1d and Table S1a), suggesting that
BM-adipocyte numbers in particular display striking sensitivity to
the presence of ALL. Importantly, ALL-associated adipocyte
suppression was unrelated to BM cellularity, confirming that
changes in adipocyte population activity reflected absolute versus
proportional losses. (Supplementary Fig. S1a and S1b). We
additionally measured adiponectin production in the marrow
plasma from ALL patients as a functional marker of BM
adiposity29, and showed it was reproducibly decreased (Fig. 1e),
consistent with the population-level losses observed histologically.
Altogether, these data clarify that the BM-adipocyte stroma is not
a prominent component of the primary tumour microenviron-
ment but the emergent niche associated with the remission
response.
To investigate how these niche dynamics relate to clinical
chemoresistance, we examined ALL cell interactions in BM
trephines from patients who failed to achieve complete remission
(>5% blasts morphologically after induction therapy). These
analyses revealed two consistent patterns across independent BM
biopsies; chemoresistant ALL cells were distributed either
interstitially throughout the marrow (Fig. 1f) or in close
neighbouring proximity to adipocytes. Thus, while chemoresis-
tance is spatially heterogeneous within the BM niche, as
previously suggested17, distinct physical interactions with the
surrounding adipocyte stroma are recurring features of drug
survival in ALL.
ALL corrupts the functioning and lineage priming of the adi-
pocyte precursor mesenchymal stromal-cell (MSC) population.
To investigate the mechanism by which adipocytes are depleted in
ALL-BMMs, we performed a global evaluation of the BM-MSC
axis, hypothesizing that these precursors for BM-adipocyte gen-
eration were disrupted by ALL disease. We found that MSCs could
be generated with similar success from ALL vs healthy control BM
(Table Supplementary 2a) and that the BM-MSC phenotype was
highly conserved in ALL disease (Supplementary Fig. 2a)30 con-
firming these isolates were bona fide MSCs. We further assessed
the growth properties of ALL-MSCs using the growth rate in vitro
as a measure of proliferative potential and where cell numbers
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permitted functional assessment of clonogenic capacity. We
observed a nonuniform growth response in ALL-MSCs, reflecting
expected differences in tumour and host biology. We therefore
dichotomized growth data into high and low performers defined
by the mean number of ALL-MSCs (Fig. 2a). High performers
constituted a small subgroup (3/12, 25%) whose growth activity
and CFU-F were indistinguishable from healthy BM-MSCs;
however, most ALL-MSCs (9/12, 75%) demonstrated significantly
reduced growth capacity (mean ± SEM: ALL-MSCs 0.095 ± 0.046
vs healthy-MSCs 0.254 ± 0.041), although interestingly, had
retained their CFU-F forming potential (Fig. 2b), suggesting that
the low expansion capacities of these ALL-MSCs were princi-
pally driven by defective colony growth vs colony formation. We
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following in vitro developmental induction. Unexpectedly, we
found that ALL-MSCs had a significantly enhanced capacity for
adipogenic differentiation (2.87 ± 0.29-fold increase; n= 7;
***p= 0.0003), as determined by cell staining for adipocyte-
specific fatty acid binding 4 (FABP4) (Fig. 2c), without any reci-
procal disturbance in osteogenesis (Fig. 2d), indicating that ALL
pathogenesis significantly affects the lineage priming of MSCs in
an adipocyte-biased manner. As the adipogenic potential of BM-
MSCs in AML disease and similar conditions has been shown to
decrease31,32, although not consistently33, this raises the possibility
that altered differentiation fates in ALL-MSCs may represent a
tumour-specific interplay.
To test the possibility that ALL cells may directly induce
changes in their surrounding stromal cells, we tested the effect of
leukaemic serum on healthy age-matched MSC stroma (Fig. 2e).
We found that enhanced adipocyte commitment could be
reproduced by exposing healthy MSCs to leukaemic but not
HSC-enriched GCSF-mobilized peripheral blood (GMPB)-con-
ditioned media, confirming a direct role of leukaemia specific
factors in altering the cell fate determination of BM mesenchymal
stroma.
Next, to gain further insight into the transcriptional
programmes underlying the altered functionality and commit-
ment of ALL-MSCs, we performed RNAseq studies on MSCs
from three healthy and three low-performer ALL-BMs (ALL12,
ALL13, ALL22) at the P4 expansion stage. Three-dimensional
principal component visualization clearly differentiated ALL-
MSCs from their healthy counterparts based on log2 transformed
unsupervised global profiles suggestive of disease-specific
transcriptional modulation (Fig. 2f). Further gene set enrichment
analysis (GSEA) of these global RNA-seq datasets identified
genes involved in cellular metabolism and multiple aspects of cell
cycle function (Fig. 2g, h) as preferentially downregulated in
ALL-MSCs, whereas no gene sets were identified as significantly
(FDR q-value<0.05) upregulated. Notably, the BURTON_ADI-
POGENESIS KEGG pathway, which specifies a committed gene
program for adipocyte differentiation, was not significantly
enriched in the ALL-MSCs, confirming i) that ALL-MSC isolates
were not adipocyte precursor cells and ii) that ALL-MSCs are
poised rather than committed to programmed adipocyte
differentiation. To validate the findings of GSEA suggesting
attenuated cell cycle function in ALL-MSCs, we performed a
functional analysis in four low-performer ALL-MSCs (ALL12-14,
ALL22) at the P4 expansion stage. This analysis confirmed
that ALL-MSCs display slower proliferation kinetics (Fig. 2i),
providing a potential mechanistic basis for their impaired growth
function in vitro.
Collectively, our data suggest that ALL disease corrupts
regenerative growth and the differentiation of MSCs. Such
perturbations may lead to a reduced number of MSC precursors
inhabiting the BM of ALL, which may account for disease-
associated loss of adipocyte stroma. However, accumulation of
adipocyte-primed MSCs, in the context of adipocyte-depleted
ALL-BM, leads to the proposal that their differentiation must be
stalled, most likely through a blast-specific mechanism, an effect
that likely is reversed upon ALL clearance.
Adipocytes create a tumour-suppressive niche in ALL. To
explore the possibility that variations of adipocyte activity within
the BMM contribute a meaningful pathophysiological role vs
merely serving as a by-product of the leukaemic process, func-
tional studies were performed to establish the effects of adipocyte
stroma on ALL cells using an in vitro coculture strategy
employing primary human adipocytes differentiated from healthy
BM-MSCs or adipocytes derived from murine 3T3-L1 cell lines34
together with ALL cell lines; Nalm-6, REH and RS4;11 (Fig. 3a).
Surprisingly, we observed that both 3T3-L1 and primary BM-
MSC adipocytes robustly impaired the growth capacity of
independent ALL cell lines with high reproducibility compared
to log phase monocultures (Fig. 3b), with evidence of a dosage-
dependent effect, as indicated by lower relative growth rates in
3T3-L1 adipocyte conditions that have more complete adipocyte
conversion (Supplementary Fig. 3a). Notably, basal growth of
ALL cell lines was unaffected by coculture with primary
osteoblasts, primary BM-MSCs and 3T3-L1 preadipocytes,
confirming that adipocytes inhibited in vitro ALL growth in a
tissue-specific manner and that this was a direct causal effect.
Mechanistically, we confirmed that adipocyte niches did not lead
to appreciable apoptosis (Supplementary Fig. 3b) but instead
antagonized cell cycle progression, resulting in reproducible
expansion of a quiescent cell pool accompanied by variable
reductions in S/G2/M progression (Fig. 3c). Thus, interaction
with adipocyte niches in vitro suppresses the constitutive
proliferation of ALL cells and lowers cell cycle transit in a causal
manner. Furthermore, these data confirm that in vitro murine
3T3-L1-derived adipocytes34 robustly recapitulate key responses
of primary BM-adipocyte tissue cultures thereby establishing the
reliability of these models as an experimental system. As further
validation, adipocytes derived from BM-MSCs obtained after
Fig. 1 The adipocyte BM niche is dynamically remodelled during ALL pathogenesis and treatment. a H&E-stained human BM biopsies from healthy
control, patient with ALL at diagnosis (ALL01 Diagnostic) and post remission induction treatment (ALL01 Remission Induction). Representative of five
independent healthy BM biopsies and eight independent matched pairs of ALL diagnosis and remission biopsies analysed once/biopsy. Zoomed-in images
of the boxed regions are presented below. Black arrowheads indicate BM adipocytes. Custom image analysis using Visiopharm software identifies
individual BM adipocytes as green objects. b Adipocyte numbers quantified by Visiopharm analysis in healthy controls (n= 5) and paired ALL diagnosis vs
ALL remission BM biopsies (n= 8). Each datapoint denotes an independent biopsy. Data are normalized to the size of the biopsy. **p < 0.01 by one-way
ANOVA with Tukey’s multiple comparison test. c Adipocyte size quantified by Visiopharm analysis in healthy control (n= 5) and ALL diagnosis (n= 8,
ALL01-ALL08) BM biopsies. Data points denote values for individual adipocytes (>45). The mean ± SEM is shown. Statistical significance was assessed by
a Kruskal–Wallis test with Dunn’s multiple comparisons test (****p < 0.0001). d Adipocyte size quantified by Visiopharm analysis in healthy control (n= 5)
and ALL remission (rALL) BM biopsies (n= 8). Data points denote values for individual adipocytes (>72). The mean ± SEM is shown. Statistical
significance was assessed by a Kruskal–Wallis test with Dunn’s multiple comparisons test (****p < 0.0001). e Adiponectin concentrations in serum
samples from healthy control vs ALL diagnosis BM (including ALL04, ALL17 and ALL21). Adiponectin was quantified using a commercial ELISA kit. Each
datapoint denotes an independent BM serum sample. ***p < 0.0006 by a 2-sided unpaired t test. f Morphological evaluation of residual ALL disease in
H&E-stained BM biopsies from four consecutively assessed patients with an incomplete response (<5% blasts) to remission induction chemotherapy.
Individual images show ALL tumour-specific immunostaining. Red arrows indicate ALL blasts in close proximity to BM adipocytes while black arrows
denote interstitially distributed ALL disease as assigned by 2 independent reviews. The percentage of residual ALL disease was obtained from clinical
reports and is indicated in red text.
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remission induction were also assessed and were shown to induce
similar outcomes to those of healthy BM-MSC primary
adipocytes (Supplementary Fig. 3c), thus extending the relevance
of the described effects to the post-treatment niche setting.
To investigate the importance of these data in an in vivo
context, experiments were conducted comparing in vivo ALL
cellular response in adipocyte-rich (tail-BM and gonadal fat) vs
adipocyte-poor (femur) tissues using xenotransplantation
assays of the Nalm-6 ALL cell line and four independant
primary B-ALL tumours (Fig. 3d). We included gonadal fat
based on the finding that 3T3-L1 adipocytes, a non-BM restricted
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executed effects on ALL cells. We first confirmed that NSG mice
have low BM-adipocyte abundance in femoral BM, as demon-
strated by osmium tetroxide staining (Fig. 3e), validating the
study of femoral BM as a model of adipocyte-poor marrow. We
found that both the xenotransplanted Nalm-6 ALL cell line
(Fig. 3f) and primary ALL cells from four genetically distinct
tumours (Fig. 3g) had significantly less leukaemia cell engraft-
ment in all adipocyte-rich tissues at 3-4 and 6-8 weeks following
transplantation respectively when compared to adipocyte-poor
femoral BM, which demonstrated robust leukaemia engraftment
at this time. Thus, consistent with the functional outcomes
in vitro (Fig. 3b), ALL cells in vivo demonstrate limited expansion
in adipocyte niches. Further direct phenotypic characterization of
engrafted tumours confirmed that ALL cells resident in adipocyte
niches were marked by increased cellular quiescence (Fig. 3h, i)
and reduced cell cycle G1/S/M status, substantiating the concept
that adipocytes support tumour dormancy states. These results
represent a broader biological relationship with ALL than
previously described24 and are in line with reported effects in
HSCs35.
Taken together, these data conceptualize adipocytes as key
drivers of ALL cell plasticity and switchers of cellular fate from
constitutive proliferator status to a phenotype characterized by
proliferative quiescence. These data support the concept that
changes in BM-adipocyte population dynamics facilitate ALL in
distinct ways. Compromised adipocyte activity, possibly through
ALL cells actively deregulating adipocyte generation, eliminates a
key inhibitory niche for ALL, thereby enabling the emergence of
leukaemia. However, reinstated adipocyte activity during the
treatment response evolves a pro-tumour dormancy setting that
could participate in antagonizing chemotherapy targeting.
Adipocyte niches restrict protein synthesis in ALL via non-
canonical factors. We next sought to define the mechanism(s)
underlying the dormancy/growth suppressive response of ALL
cells to microenvironmental adipocytes. We selected 3T3-L1
adipocyte models to initialize these studies based on their strong
recapitulation of the BM-adipocyte interplay (Fig. 3b, c) and the
ability to control for major confounding effects, e.g., non-
adipocyte stromal-cell contamination (Supplementary Fig. 3a),
thus, overcoming the principal limitation of in vivo adipocyte
niche systems36.
Initial assessments confirmed that a cell cycle checkpoint
mechanism was not engaged in adipocyte-conditioned ALL cells
(Supplementary Fig. 4a), suggesting that the phenotypic response of
ALL cells to the adipocyte stroma likely occurs through an indirect
vs a direct effect on the cell cycle. Next, given that lipid crosstalk is
the principal mode of adipocyte-tumour cell interplay described to
date37–39, we assessed the contribution of these events to the
adipocyte-specific effects on ALL. Lipid profiling studies established
that +24 h following 3T3-L1 adipocyte coculture, Nalm-6 cells
demonstrated an accumulation of intracellular lipids, the compo-
nents of which included oleic acid, a major subclass of fatty acid,
which reflected, in part, a direct transfer of fatty acid from adipocytes
to ALL, consistent with previous reports37–39. However, further
functional evaluation of the fatty acid flux pathway confirmed that
this was not a major factor driving ALL growth suppression
(Supplementary Fig. 4b-j and Supplementary Discussion). Given
that these candidate mechanisms could not robustly account for the
adipocyte-ALL interplay, we next turned to unbiased screens. Here,
we reasoned that the rapid adaptive response of ALL cells (Fig. 3b)
suggests that global signalling and transcriptional networks were
being stimulated. We therefore subjected Nalm-6 cells cocultured
with 3T3-L1 adipocytes to quantitative LC-MS/MS phosphoproteo-
mic analysis at two timepoints (+24 h and +72 h), comparing
outcomes between 3T3-L1 preadipocyte coculture to control for
general stromal effects. At both timepoints, we detected a substantial
impact of adipocyte conditions on the ALL phosphoproteome (log2
FC ≥ 1 or log2 FC ≤−1, p-value ≤ 0.05) involving 1,808 and 981
phosphorylation sites at +24 h and +72 h, respectively (Fig. 4a),
consistent with large-scale rebalancing of these networks. Gene
Ontology (GO) enrichment analysis was conducted on these
significantly modulated phosphosites (Fig. 4b), revealing that at
+24 h, terms related to biosynthetic and metabolic processes
inclusive of lipid metabolism (e.g., lipid metabolic process,
triglyceride catabolic process) were overrepresented, likely reflecting
the ensuing effects of lipid translocation from 3T3-L1 adipocytes at
this time (Supplementary Fig. 4b, c). In addition to these expected
modulations, pathways relating to diverse aspects of protein
homeostasis (protein translation, translation initiation, elongation
“proteostasis”) and mRNA processing were significantly over-
represented in adipocyte-modulated ALL cells at both +24 h and
+72 h, albeit switching from upregulation to repression over time.
Notably, kinase-substrate enrichment analysis (KSEA), a platform to
systematically infer the activation of given kinase pathways from
mass spectrometry-based phosphoproteomics40, identified a general
increase in proliferation-associated signalling networks, e.g.,
MAP2K1 JAK2, at +24 h despite robust suppression of cell growth
(Supplementary Fig. 4k), indicating that mitogenic signalling was not
acutely disrupted to explain the acute growth suppression.
Fig. 2 ALL corrupts the functioning and lineage priming of the adipocyte precursor mesenchymal stromal-cell (MSC) population. a Growth outcomes of
ALL-MSCs (ALL12-ALL23) at P1. Each datapoint denotes an independent BM. ALL-MSCs were divided into high and low performers defined by the group mean.
Horizontal line denotes the median *p < 0.0132, ***p < 0.001. b CFU-F numbers from seven independent ALL (ALL15-17, ALL19-21 and ALL23) and healthy-BMs
after +10 days under MSC differentiation conditions. c Adipocyte-specific FABP4 staining in ALL vs healthy-MSCs (left) and FABP4 fluorescence quantification
(right). Images are representative of seven and six independent BM samples, respectively analysing 100 cells/sample. d Osteocalcin staining in ALL vs healthy-
MSCs (left) and osteocalcin fluorescence quantification (right). Images are representative of six and five independent BM samples, respectively. For (c) and (d)
comparisons are between each individual ALL-MSC and the aggregated mean of healthy-MSCs. Horizontal line denotes the median; boxes extend from the 25th
to the 75th percentile. e Representative micrographs (left) showing intracellular lipid staining with oil red (magnification, ×10; scale bar, 200 µm) following in vitro
adipogenic differentiation in the absence or presence of conditioned media (CM) from cultured GMPB, from n= 3 biologically independent samples or from ALL
cell lines (Nalm-6, REH and RS4;11). Oil red staining was quantified in three independently assayed wells/condition from one experiment. **p=0.002,
***p=0.0004. f Principal component analysis of global RNA-seq data from ALL-MSCs (ALL12-14) and age-matched healthy-MSCs (n= 3). Each dot represents
an individual BM-MSC. g GSEA comparing RNA-seq-generated global transcriptomes of ALL-MSCs (n= 3) vs healthy-MSCs (n= 3) by KEGG pathway
annotation. Significance was assigned by FDR q-value<0.05. Bars in green correspond to downregulated pathways. h Gene set enrichment plot for the KEGG cell
cycle pathway demonstrating significant downregulation of these gene sets in ALL-MSCs. i Ki67 cell cycle analysis of ALL-MSCs (n= 4) vs healthy-MSCs
(n= 4). Statistical comparisons are between each cell cycle stage. *p=0.029. Unless otherwise stated, all data are presented as mean values ± SEM values of
independent experiments (n= 4 in (a), n= 3 in (b), n= 1 in (e) and n= 3 in (i). Statistical significance was assessed using Kruskal–Wallis test with Dunn’s
multiple comparisons test (a–d), 2-sided unpaired t tests (e), two-sided Mann–Whitney U test (i). *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001) or the
precise p-value where indicated. ns, not significant. NES, normalized enrichment score; FDR false discovery rate.
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Gene expression profiles of adipocyte-cultured Nalm-6 cells at
+24 h assessed by RNAseq indicated predominantly low-
magnitude changes (Fig. 4c, Supplementary Fig. 4l, m) with the
difference in the adipocyte imprinted Nalm-6 transcriptome
(adjusted p-value < 0.05) defined by only 547 genes, of which only
a low number of genes (n= 50) met conventional DEG
thresholds of log2 FC ≥ 1 or log2 FC ≤−1.GSEA revealed few
overrepresented pathways (Fig. 4d), namely, glycolysis (p-value <
0.05, FDR q-value=0.03) and its subcomponent fructose
biosynthesis (p-value < 0.05, FDR q-value=0.03), likely reflecting
the altered intracellular lipid environment (Supplementary Fig 4b,
c). Notably, and in line with the phosphoprotetomics data,
functions related to mRNA processing and multiple aspects of
protein homeostasis (folding, amino acid metabolism, translation,
ribosome biogenesis) were common pathways most under-
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Together, these comparative results indicate that the acute
response of ALL cells to adipocyte stimulation is characterized by
significantly altered phosphorylation networks and, to a lesser
extent, transcriptional events affecting cellular metabolism, a
predicted outcome of ALL-adipocyte interaction, as well as major
unanticipated effects on posttranscriptional processes and the
protein translation network.
Given that protein homeostasis was a major cellular process
modified by the adipocyte stroma, we next assessed its
significance functionally by assessing its endpoint, global protein
translation, using the O-propargyl-puromycin (OP-Puro) incor-
poration assay as a label of translational activity. The results
demonstrated that compared to both control conditions, mono-
culture and 3T3-L1 preadipocytes, Nalm-6 ALL cells subjected to
3T3-L1 adipocyte coculture demonstrated strikingly lower OP-
Puro incorporation, with very low technical and biological
variability, achieving translational attenuation similar to that of
cycloheximide (CHX), a robust inhibitor of protein translation
(Fig. 4e). Similar outcomes were achieved in other ALL cell lines
(Supplementary Fig. 4n), indicating that lowered rates of protein
synthesis were not cell line specific. Importantly, differences in
OP-Puro incorporation were not due to loss of fluorescence,
which we confirmed occurred much later; 3 h after OP-puro
administration (Supplementary Fig 4o). Moreover, there was no
increased clearance of OP-puro containing polypeptides (Supple-
mentary Fig. 4p) and no saturation in the OP-puro signal
(Supplementary Fig. 4q). Furthermore, a similar loss of OP-Puro
incorporation was also found in ALL cells cocultured with
primary BM-MSC-derived adipocytes (Supplementary Fig. 4r),
confirming that this was a relevant biological interaction not just
restricted to the 3T3-L1 model system.
Next, to test whether differences in OP-puro are explained by
differences in the cell cycle, we assessed OP-puro according to
DNA content. We found that 3T3-L1 adipocytes still imposed
significantly lower protein synthesis in ALL cells in both G0/G1
and S/G2/M (Fig. 4f and Supplementary Fig. 4s). Therefore, lower
rates of protein synthesis in ALL cells were not simply a
consequence of increased quiescence. Importantly, these findings
were also consistent with analyses performed using human ALL
samples in vivo. Two primary ALL tumours (ALL24 and ALL25)
previously validated as growth repressive/dormancy responsive to
in vivo adipocyte microenvironments (Fig. 3g, i) were subjected
to repeated xenografting followed by ex vivo staining with OP-
Puro. We found that primary ALL cells in vivo also demonstrated
restricted protein translation in adipocyte-rich niches indepen-
dent of the cell cycle stage (Fig. 4g), thus recapitulating the
findings obtained with ALL cell lines in vitro; however, the effect
was of lower magnitude, possibly due to some recovery of protein
translation following a longer period of microenvironmental
extraction.
Taken together, these data demonstrate that adipocyte
microenvironments restrict the level of protein synthesis in
ALL cells. Such reports are of particular interest because
modulating protein synthesis is unique among prior reports of
regulatory mechanisms involving adipocyte niches31,37,39,41,42.
Furthermore, this observation directly raises the possibility that
adipocyte-mediated cell cycle failure and ALL growth suppression
reflect a limitation imposed by low proteome flux43.
To address this hypothesis, we first explored the mechanism of
adipocyte-mediated hypotranslation using the 3T3-L1 adipocyte
system. Assessment of general translation determinants established
that there were no acute changes in cell diameter (Supplementary
Fig. 4t) or compromise of transcriptional output (total RNA content,
18S or 28S ribosomal RNA) (Supplementary Fig. 4u) that explained
the loss of translational output. Moreover, key signalling pathways
representing major control points for protein translation, namely,
mTOR44 and the endoplasmic reticulum stress-induced (ER)
unfolded protein response plus correlated integrated stress response
(ISR) pathways45, were not selectively engaged in ALL cells
(Supplementary Fig. 4v) to explain the repression in protein
translation. In line with this, there was no evidence of ER stress
gene activation by either RNAseq (Fig. 4d) or RT-qPCR
(Supplementary Fig. 4w). Thus, on the basis of these orthogonal
assessments, 3T3-L1 adipocytes appear to modify ALL proteome
flux via factors independent of canonical translation cascades,
possibly suggesting that adipocytes execute their regulatory effects on
protein translation via a distinct process.
To further establish whether ALL suppression is a consequence
of adipocyte-mediated translational repression, we turned to
pharmacological approaches that modulate the level of protein
translation. Of drugs known to increase protein translation
(ISRIB, PERKi, or GCN2ib), only GCN2ib led to effective target
modulation (repressed eIF2α phosphorylation) when tested in
Nalm-6 cells (Fig. 4h), and we therefore progressed this drug to
testing in 3T3-L1 adipocyte coculture. We observed that the
addition of GCN2ib led to a partial but notable increase in
protein translation in ALL cells (Fig. 4i), which was associated
with a significant reduction in adipocyte-associated ALL cell
quiescence (Fig. 4j). Although GCN2ib treatment had no
measureable impact on short-term growth, (Supplementary
Fig. 4x), this likely reflects the incomplete rescue of protein
translation induced by this treatment. Altogether, these data
establish a causal association between lowered protein translation
status in ALL cells and adipocyte-imposed ALL quiescence and
Fig. 3 Adipocytes create a tumour-suppressive niche in B-ALL. a Schematic of the experimental setup to assess functional interactions between ALL and
adipocyte niches. b In vitro growth of ALL cell lines (Nalm-6, REH and RS4;11) in adipocyte and unrelated stromal environments over time. Primary BM-
MSCs from three independent healthy donors were evaluated alongside their corresponding osteoblast and adipocyte derivative. c Frequency of quiescent
(G0) and cycling (G1 and S/G2/M) populations in ALL cells after monoculture (−) vs adipocyte coculture (+) from experiments described in (b). Bottom
panel shows representative Ki67/DAPI staining in CD19+ -gated Nalm-6 cells at +72 h. Percentage of cells in each phase of the cell cycle is shown in red.
d Schematic showing the different microenvironments assayed for human ALL xenotransplantation studies. BM from the tail and gonadal fat are designated
adipocyte-rich niches, whereas femoral BM is adipocyte poor. Arrows point to individual adipocytes. e Osmium-stained and micro-CT-imaged BM
adipocytes in whole femurs from NSG mice at +10 days. BM-adipocyte production was stimulated by sublethal (2.5 Gy) total body irradiation and served
as a positive control. f, g Engraftment outcomes of Nalm-6 (CD19+/CD10+) and four independent primary B-ALL (CD19+CD45+) tumours following tail
vein IV injection in distinct in vivo niches. Statistical comparisons are with femur. h, i Comparison of cell cycle characteristics in Nalm-6 and primary B-ALL
xenografts respectively from experiments described in (f, g). Not tested indicates failure to perform robust cell cycle analysis due to low cell recovery. The
panel on the right shows representative Ki67/DAPI staining in CD19+ gated primary B-ALL xenografts in the indicated niches. The percentage of cells in
the G0 phase is shown in red. Data are presented as mean values ± SEM values of independent experiments (n= 3 with 2–3 replicates in (b), n= 1 in (f, h)
with n= 3 mice and n= 3 in (g, i) n= 4–5 mice. Statistical significance was assessed using 2-sided unpaired t tests (b, c, i: ALL15 and 23). ANOVA with
Dunnett’s multiple comparisons test (f, g, i: ALL24 and ALL25), two-sided Mann–Whitney U-tests (h) (*p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.001). $
$p < 0.01, $$$p < 0.001 for primary vs 3T3-L1 adipocytes. Only statistically significant comparisons are indicated (b, c).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25540-4
8 NATURE COMMUNICATIONS |         (2021) 12:5507 | https://doi.org/10.1038/s41467-021-25540-4 | www.nature.com/naturecommunications
underscore how subversion of a key housekeeping function
contributes to the establishment of a therapy-adverse state.
Adipocyte-adapted ALL proteomes increase global stress
resistance. While adipocytes are known to contribute to che-
moresistance via diverse mechanisms14,17,19,22–27, the link
between ALL resistance and ALL hypotranslational states is least
explored. In particular, given our finding that adipocyte-induced
translational loss affects ALL tumours as a whole and involves all
cell cycle stages (Fig. 4f-g), these data suggest that adipocyte
niches may not exclusively protect leukaemia cells by maintaining
them in the quiescent phase24.
To directly address whether adipocyte niches provide protec-
tive outcomes independent of target cell quiescence, we
challenged Nalm-6 ALL cells with both cell cycle-dependent
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chemoresistance, and mitotic state-independent stresses induced
by hydrogen peroxide or withdrawal of FBS. The latter would not
be expected to drive differential outcomes based on target cell
dormancy. Intriguingly, despite significantly reduced proteome
flux, adipocyte-cultured ALL cells had increased cellular fitness
against both cell cycle-dependent chemotherapy and mitotic
state-independent stressors, although as expected, the outcomes
were dependent on the individual stressors involved (Fig. 5a).
Thus, adipocytes instigate more generalized cellular fitness in
ALL cells beyond induction of cellular quiescence, which may
relate to their global effect on protein translation.
In support of this notion, ALL cells were resensitized to
chemotherapy following prolonged (+48 h) microenvironmental
extraction (Fig. 5b), when protein biosynthetic activity and
quiescence levels had normalized (Supplementary
Fig. 5b) although continued to maintain a degree of adipocyte-
imprinted resistance to mitotic state-independent stressors. Given
the possibility to pharmacologically modulate the adipocyte-
imposed restrictions on the ALL proteome using GCN2ib (Fig. 4i)
this offered the opportunity to directly test its putative
contribution to cellular fitness. Therefore, we used GCN2ib to
rescue protein translation in coculture prior to applying various
cellular stresses. We observed that under GCN2ib treatment, the
cytoprotective effect of adipocytes on ALL cells was decreased in
response to cell cycle-dependent chemotherapy, as anticipated
(Fig. 4j); however, we also observed a notable reduction in
cytoprotection against mitotic state-independent stress 49-65%
(mean ± SEM: 57% ± 2.4) (Fig. 5c). These observations indicate
that adipocytes likely enable the survival of ALL cells via 2
distinct processes: induction of cellular quiescence and its wider
suppression of protein translation.
Finally, we investigated the possibility that adipocyte-
mediated stress protection is accompanied by activation of
selective mRNA translation of proteins required for stress
mitigation45. To investigate this hypothesis, we subjected Nalm-
6 cells under 3T3-L1 adipocyte coculture to pulsed stable isotope
chromatography-mass spectrometry (SILAC)-based proteomic
analysis (Fig. 5d). As expected, we confirmed potent repression
of global protein synthesis (Fig. 5e). Of the 470 proteins
identified, 413 (87.5%) were robustly cross-identified as focally
downregulated at both +24 h and +48 h. These co-
downregulated proteins were enriched for pathways related to
translational regulation, ribosomal assembly and mRNA proces-
sing (Table 1), reflecting widespread deregulation of the
translational network. Notably, we did not detect a high
abundance of proteins subject to selective mRNA translation
(n= 7), suggesting that preferential mRNA translation was not
actively engaged. Thus, we conclude that adipocyte-induced
translational reprogramming accompanies a pro‐survival
response that does not appear to be driven by a switch to a
specialized translational programme.
Discussion
Our study highlights several important findings. First, the adi-
pocyte niche is dynamic in ALL, evolving from depleted states in
ALL disease to full reconstitution during the remission response,
confirming that these niches contribute temporally to an MRD-
associated environment. Second, we identified a protein-based
interplay regulated by the adipocyte stroma that restricts protein
translation in ALL cells. Importantly, adipocyte-imposed
restriction of protein translation played a direct role in regulat-
ing ALL cell quiescence. To the best of our knowledge, this is the
first report to link the regulation of ALL quiescence with
extrinsically mediated control of protein synthesis, although a
similar parallel has been reported for HSCs involving exogenous
angiopoietin46. Consistent with our findings, the level of trans-
lational activity has also been shown to regulate HSC
maintenance47 further emphasizing the connection between
quiescence-proliferation decisions and protein dynamics. We
further show that reduced levels of global protein synthesis are
associated with increased cellular fitness in ALL cells (Figs. 5a–c)
and that this protection was not limited to the feature of cellular
quiescence but encompassed broader multitrait resistance. In this
way, adipocytes act not as selective chemo-survival factors but as
providers of broader tumour cell protection than previously
envisaged48. Notably, our finding that adipocytes enhance the
survival and persistence of ALL cells through non-cell-
autonomous suppression of the ALL proteome resonates with a
form of biosynthetic stress resilience that has recently gained
recognition as a cell-intrinsically determined process49, empha-
sizing the importance of attenuated biosynthetics as a critical
mark of treatment resistance. How adipocyte-imposed hypo-
translation leads to improved multistress resistance in ALL cells
was not attributable to a switch to selective translation of pro-
survival proteins, as reported for other protein suppression
states44,45. This opens up the conceptual possibility that other
factors, such as enhanced proteome quality, may play a role,
Fig. 4 Adipocyte niches restrict protein synthesis in ALL via non-canonical factors. a Venn diagram of significant phosphosites identified in Nalm-6 cells
cultured with 3T3-L1 adipocytes at +24 (green) and +72 h (red). Bracketed values denote the corresponding number of proteins. b Pathway analysis of the
altered phosphoproteins from (a). Z-score, red: ≤−1.5, pathway underrepresented; green: ≥+1.5, pathway overrepresented. GO terms are grouped into
categories that were hand curated. c Differential transcription level (log2) between Nalm-6 cells cultured with 3T3-L1 adipocytes vs 3T3-L1 preadipocytes
at +24 h. Differentially transcribed genes (FDR q-value<0.05) are highlighted in red for each indicated log2 FC range. Dashed red lines represent log2 FC
thresholds −1 and 1. Data derived from RNAseq of three replicates/condition. d GSEA comparing RNAseq-generated global transcriptomes of 3T3-L1
adipocyte vs 3T3-L1 preadipocyte cultured Nalm-6 cells by KEGG pathway annotation. Significant pathways defined by FDR q-value <0.05. (Red bar:
upregulated pathways, Green bar: downregulated pathways). e OP-Puro incorporation by Nalm-6 cells under 3T3-L1 preadipocyte (grey) or 3T3-L1
adipocytes (blue) coculture relative to monoculture. Nalm-6 monocultures treated with CHX, 10 µg/mL for 10min (black), served as a positive control.
Representative histograms of OP-Puro fluorescence are shown on the right. f OP-Puro incorporation in vitro in Nalm-6 cells in G0/G1 vs S/G2/M fractions
+72 h after coculture with 3T3-L1 preadipocytes (grey) or 3T3-L1 adipocytes (blue). Data are normalized to monocultures. g OP-Puro incorporation in
CD19+/CD45+ xenografted primary B-ALL cells (ALL24 and ALL25) harvested from femoral (blue) and tail (red) BMs according to cell cycle stage.
ALL24 G0/G1 p= 0.0002, S/G2/M p= 0.0003; ALL25 G0/G1 p= 0.017, S/G2/M p= 0.045. h Western blot showing p-eIF2α levels in Nalm-6 cells
(5×106) after 72 h treatment with ISRIB, PERKi, or GCN2ib or Thapsigargin (250 nM), the latter serves as a positive control. (representative of two
independent experiments). i OP-Puro incorporation in Nalm-6 cells cocultured with 3T3-L1 adipocytes after 72 h of GCN2ib (5ug/mL) vs vehicle treatment.
The results are expressed relative to the OP-Puro fluorescence of Nalm-6 in 3T3-L1 preadipocyte coculture. **p= 0.0022. j Frequency of G0 cells in Nalm-
6 cells cocultured with 3T3-L1 adipocytes after 72 h of GCN2ib (5ug/mL) vs vehicle treatment. **p= 0.0017. Data are presented as mean values ± SEM
values of independent experiments (n= 2 in c, n= 3 in (e, f) assessing triplicates, n= 2 in (g) with n= 4 mice, n= 2 in (i, j) assessing triplicates. Statistical
significance was assessed using 2-sided unpaired t tests (e, f, g, i, j) **p < 0.01. ***p < 0.001, ****p < 0.0001 or the precise p-value where indicated.
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analogous to paradigms in other model organisms50. Although
these aspects are yet to be resolved, the observation that
adipocyte-regulated loss of protein translation in ALL cells pro-
motes ALL resistance adds to the increasing repertoire of stromal
mechanisms that present a challenge to therapeutic success. In
vivo targeting of adipocytes should provide further insight into
this process but was not applied here due to the inability to
modulate BM adipocytes exclusively without introducing sig-
nificant confounding variables51–53. Therefore, appropriate
model development will be essential to overcome this limitation
and to establish the full in vivo potential of adipocytes in ALL
disease/resistance.
Although our results implicate GCN2 as the potential factor
determining ALL translational repression, given its rescue when
GCN2 is inhibited (Fig. 4i), the lack of any selective increase in
eIF2α phosphorylation under adipocyte conditions (Supplemen-
tary Fig. 4v) together with no orthogonal features of activated ISR
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incomplete phenotype reversal despite potent eIF2α inhibition
would argue against this factor being the principal driver. We
predict that the mechanism coupling adipocytes with the leu-
kaemia proteome is complex and beyond the scope of this report
given that canonical pathways controlling protein translation
were not obvious. Significantly, our data do yield important
insights into potential entry points for therapeutic intervention.
First, therapeutic modulation of GCN254 may disrupt the reg-
ulatory impact of adipocytes on ALL protein synthesis, thereby
limiting the development of ALL cell phenotypes specifi-
cally linked to this process. Second, as adipocytes restrict the ALL
proteome through direct interaction with ALL cells (Supplemen-
tary Fig. 5c, d), the latter showing importance in scenarios
of clinical chemoresistance (Fig. 1), this suggests that physical
interactions between ALL cells and adipocytes should be targeted
to limit phenotypic plasticity arising from this specific stro-
mal crosstalk which otherwise serves to increase tumour cell fit-
ness. Further work is therefore warranted to deeply characterize
the adipocyte-ALL interactome to pursue this potentially profit-
able avenue. The tractability of such approaches is supported by
our data, which demonstrates that ALLproliferation loss, lowered
proteome flux and chemoprotection are reversible states upon
microenvironmental withdrawal (Fig. 5b and Supplementary
Fig. 5d).
Our results merit comparison with the wider published data
relating to adipocyte niches and leukaemia. While our data are in
broad agreement with reports demonstrating that adipocyte
stromal microenvironments are active modulators of the
tumoural phenotype, the tremendous potential for these stroma
to elicit both tumour- and tissue-dependent outcomes is also
specifically highlighted.
In AML, where specifically evaluated, the adipocyte stroma has
been shown to enhance AML proliferation as well as cellular
survival37, similar to reported effects in a variety of solid
cancers38,55,56. In line with this, adipocytes located in gonadal
tissue play a supportive role in CD36 +AML leukaemia stem cell
(LSC) maintenance and expansion39. The main mechanism
defining the adipocyte-AML interplay relates to facilitated fatty
acid transfer37,39. As our descriptions appear diametrically
opposite, both in terms of the effect of adipocytes on cellular
growth, the role of fatty acids and the nature of the modulation,
which is a contextual and reversible property of interactions with
adipocyte niches, this supports the notion of lineage specificity in
adipocyte niche function. Thus, while adipocyte depletion states
are characteristic of AML disease31,57 as well as other conditions,
its biological significance will be defined by the interplay specific
to the tumour cell type. Our study defines a conceptual frame-
work (Fig. 6) specific to the B-ALL disease-remission transition,
based on the interplay demonstrated with adipocyte stroma and
should not be directly extrapolated to other conditions exhibiting
BM-adipocyte dynamics.
Overall, our report provides insights into the versatility of
adipocytes in their capacity for tumour adaptation. The func-
tional coupling between adipocytes and ALL proteomes goes
Fig. 5 Adipocyte-adapted ALL proteomes increase global stress resistance. a Cell viability of Nalm-6 cells from monoculture (black, n= 8) vs 3T3-L1
adipocyte coculture (blue, n= 8) in the presence of the indicated chemotherapeutic agents or mitosis-independent stressors (no FBS and hydrogen
peroxide). Data are presented relative to vehicle controls. b Cell viability of Nalm-6 cells after +48 h recovery from 3T3-L1 adipocyte coculture (blue,
n= 4) or from monoculture (black, n= 4) after exposure to mitosis-dependant chemotherapy or mitosis-independent stressors (no FBS and hydrogen
peroxide). Data are presented relative to vehicle controls. c Cell viability of Nalm-6 monocultured (black, n= 3) or 3T3-L1 adipocyte-cocultured Nalm-6
cells (blue, n= 3) in the presence of GCN2ib treatment (5 µg/mL) and the indicated cellular stressors. d Schematic for pulsed SILAC-based proteomic
analysis. Nalm-6 cells cocultured with either 3T3-L1 adipocytes or preadipocytes were pulsed at +24 h and at 48 h with either ‘heavy’ or ‘medium’ isotope-
labelled amino acids. Following a 4 h incubation, Nalm-6 cells were separated from their microenvironment for protein extraction. Lysates were mixed in
equal amounts (between heavily and medium labelled samples at each time point), digested, fractionated and analysed using mass spectrometry.e Scatter
plot showing the normalized log2 ratio of proteins detected following pulsed SILAC-based proteomic analysis in Nalm-6 cells cocultured with 3T3-L1
adipocytes (Adipo) relative to preadipocytes (preadipo) at +24 h vs 48 h from one experiment. Blue Arrows describe the direction of change in adipocyte-
specific coculture. Data are presented as mean values ± SEM values of independent experiments (n= 2 in (a) with four replicates, n= 1 with four replicates
in (b, c). Statistical significance was assessed using 2-sided unpaired t tests (a, b for the single-agent treatments), Mann–Whitney U test for combination
chemotherapy treatment (b) One-way ANOVA followed by Tukey’s test for multiple comparisons c. **p < 0.01, ***p < 0.001, ****p < 0.0001.
Table 1 Pathway analysis of the co-downregulated proteins (n= 413) at +24 and +48 h in Nalm-6 cells cocultured with 3T3-L1
adipocytes, as detected by pulsed SILAC. Pathway enrichment was assessed by two-sided Fisher’s exact tests with a
Benjamini–Hochberg FDR of 5%. Pathways with an enrichment >2 are presented.
Category Pathway Enrichment factor P-value Benj. Hoch. FDR
1 Keywords Elongation factor 3.1071 0.00034546 0.01708
2 GOCC chaperonin-containing T-complex 3.1071 0.0001099 0.003187
3 Keywords rRNA-binding 2.7618 0.00067496 0.026323
4 GOCC cytosolic small ribosomal subunit 2.3052 1.25E−06 6.84E−05
5 GOCC small ribosomal subunit 2.2597 1.31E−06 6.84E−05
6 GOBP positive regulation of translation 2.244 0.00044973 0.036325
7 GOBP regulation of cysteine-type endopeptidase activity 2.1749 0.00044019 0.036147
8 KEGG Ribosome 2.1128 4.68E−11 1.04E−08
9 GOBP nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 2.0963 7.60E−12 7.49E−09
10 GOBP nuclear-transcribed mRNA catabolic process 2.0714 1.11E−12 2.73E−09
11 GOBP mRNA catabolic process 2.0605 1.02E−12 2.73E−09
12 Keywords Citrullination 2.0315 0.00035833 0.01708
13 GOCC cytosolic large ribosomal subunit 2.0232 5.17E−06 0.00018405
14 GOCC cell cortex part 2.0196 0.0019023 0.045137
15 GOBP RNA catabolic process 2.0196 1.73E−12 2.83E−09
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beyond known players of adipocyte-tumour cell interplay and
represents an important mechanism of niche-driven resistance
that should be targeted to increase therapeutic success.
Methods
Human samples. The use of human samples, collection and publication of
individual-level clinical data was approved by the NRES Committee London; City
& East Research Ethics Committee 10/H0704/65. The conduct of the study was
fully compliant with the ethical approval. Pretreatment bone marrow and per-
ipheral blood samples containing >80% blasts were collected from adult patients
with ALL at diagnosis and cryopreserved after mononuclear cell (MNCs) isolation
using Lymphoprep™ (07851, STEMCELL Technologies) based density gradient
centrifugation. Patient- and disease-specific features are summarized in Supple-
mentary Table 3. Adult healthy control BM-MNCs were purchased from Lonza
(2M-125C) (median age: 27 years, range: 21-47). BM trephine biopsies were
obtained from the posterior iliac crests of patients as part of routine diagnostic
procedures and were sourced from the diagnostic laboratories of St Bartholomew’s,
Royal Marsden and Christie Hospitals U.K. Healthy trephines were selected from
adult lymphoma staging biopsies where histological involvement had been exclu-
ded. Peripheral blood stem cells were obtained from GCSF-mobilized healthy
donors (GMPB) who were undergoing an allogeneic stem cell donation procedure
on the COBE Spectra apheresis system (Caridian BCT, Lakewood, CA).
Histological analysis. Quantitative analysis of adiposity in patient diagnosis,
remission (<5% marrow blasts defined morphologically) and healthy control tre-
phine biopsies was determined using a custom analysis protocol package (APP)
designed using AuthorTM (Visiopharm). In brief, formaldehyde-fixed paraffin-
embedded sections of human trephine biopsies were stained with haematoxylin
and eosin (H&E) to visualize the gross anatomy of BM tissue. Whole H&E slides
were scanned using a Pannoramic 250 Flash at × 20 magnification and then
imported into Visiopharm software. Regions of interest (ROIs) consisting of the
haematopoietic marrow space were delineated. Trabecular bone, areas of hae-
morrhage, processing or tissue damage artefacts or non-marrow adipocytes were
excluded from analysis. ROIs were verified by expert histopathological review.
Filters were applied to the input image combining median, standard deviation
and multiplication of pixel neighbourhoods followed by threshold analysis to
distinguish the empty adipocytes from the background tissue. Post-
processing scripts based on minimum and maximum area and form factor
further restricted measurement to only adipocytes. A separation script was
applied to distinguish individual adipocytes arranged in clusters. Output
variables from the APP were adipocyte count and size along with the input area
of the ROI. Immunostaining of BM trephines was performed on four μm slides
for CD79a (clone SP18, Roche), CD34 (QBend 10, Roche), CD22 (clone
SP104, Roche), Tdt (5267811001, Roche) and PAX5 (EPR3730, Abcam,).
Staining was performed on the Ultra Ventena platform using the Optiview
DAB detection kit (Roche 760700). Proximity relationships between drug
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Fig. 6 a Adipocyte niche function in ALL disease. Graphical abstract showing the temporal course of adipocyte niches across the ALL disease-remission
transition and its pathophysiological relevance based on the demonstration of adipocyte-driven modulations in ALL cell phenotype.
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and verified by an expert haematopathologist. Only consensus events were
reported.
Adiponectin testing. BM serum samples were collected from patients with newly
diagnosed ALL before the initiation of treatment. For control samples, BM serum
was utilized from two sources: patients with < stage III diffuse large B cell lym-
phoma without BM involvement (n= 5) or healthy donors (n= 2). Adiponectin
measurements were performed in technical duplicate using the commercial Ray-
Bio® Human Adiponectin ELISA kit (ELH-Arcp30).
Generation of mesenchymal stromal cells. BM-MNCs were seeded at densities of
10 × 106 cells per 175 cm2 in MesenCult™ MSC Basal Medium (05401, STEMCELL
Technologies) supplemented with MesenCult™ MSC Stimulatory Supplement
(05402, STEMCELL Technologies), 100 units/ml penicillin and 100 µg/ml strep-
tomycin (15140122, Thermo Fisher Scientific), 2 mM L-glutamine and 1 ng/ml
recombinant human FGF (233-FB, R&D Systems) and incubated at 37 °C and 5%
CO2 under humidified conditions for 21 days. The culture medium was changed on
day 2 and every week thereafter to remove nonadherent cells. On day 21, adherent
cells, corresponding to BM-MSC populations at P1, were detached using a Trypsin/
EDTA Solution (R001100, Thermo Fisher Scientific) and counted using the LUNA-
FL™ Dual Fluorescence Cell Counter (Logos Biosystems) and Acridine Orange/
Propidium Iodide Staining (F23001, Logos Biosystems). A subset was subjected to
phenotypic characterization using the Human MSC Analysis Kit (562245, BD
Biosciences) to ascertain whether the criteria defined by the International Society
for Cellular Therapy were met: ≥95% expression of CD73, CD90 and CD105 and
≤2% expression of the haematopoietic and endothelial cell markers CD34, CD45,
CD11b, CD19 and HLA-DR30. The rest of the cells were passaged to a
maximum of P4.
Colony-forming unit fibroblast (CFU-F) assays. For CFU-F assays, BM-MNCs
were plated in duplicate or triplicate at densities of 1 × 106 cells per 25 cm2 flask
and cultured as described under “Generation of Mesenchymal Stromal Cells”. After
10 days, colonies (>50 cells) corresponding to CFU-F were stained with 0.5%
crystal violet (C6158, Merck KGaA) and counted by light microscopy58.
MSC differentiation. The ability of MSCs to differentiate into multiple
mesenchymal lineages was examined using the Human Mesenchymal Stem Cell
Functional Identification Kit (SC006, R&D Systems). All differentiation studies
were undertaken at the P2-P3 stage, and MSCs were cultured in MEM α medium
(22561021, Thermo Fisher Scientific) supplemented with 10% heat-inactivated
foetal bovine serum (FBS; 10500064, Thermo Fisher Scientific), 100 units/ml
penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine prior to inducing dif-
ferentiation. Adipogenic differentiation was initiated in confluent MSC cultures by
adding adipogenic differentiation medium containing 1% adipogenic supplement.
For osteogenic differentiation, MSCs were grown to 60–70% confluence prior to
initiating osteogenic differentiation using osteogenic differentiation medium con-
taining 5% osteogenic supplement. The culture medium was refreshed every 3 days
for a total duration of 21 days, after which differentiated MSC cultures were set up
for coculture. For immunofluorescence studies, MSCs were differentiated on sterile
glass coverslips. For osteogenic differentiation, coverslips were coated with 1 µg/ml
fibronectin (1918-FN, R&D Systems) to prevent cell detachment. Differentiated
cells were fixed with 4% PFA for 20 min followed by washes in DPBS (no calcium,
no magnesium; 14190094, Thermo Fisher Scientific). Cells were permeabilized and
blocked with 0.1% Triton X-100 and 2% BSA (A9647, Merck KGaA) in DPBS for
45 min prior to incubation with either an unconjugated goat polyclonal antibody
recognizing FABP4 (10 μg/mL; AF1443, R&D Systems) followed by a donkey anti-
goat antibody conjugated to Alexa-647 (1:500; A-21447, Thermo Fisher Scientific)
or an unconjugated mouse monoclonal antibody against osteocalcin (10 μg/mL;
MAB1419, R&D Systems) followed by a goat anti-mouse antibody conjugated to
Alexa-488 (1:500; A-11001, Thermo Fisher Scientific) to identify adipocytes and
osteoblast cells, respectively. Slides were mounted with ProLong™ Gold Antifade
Mountant with DAPI (P36931, Thermo Fisher Scientific), and fluorescent images
were acquired at ×20 magnification using a Nikon Eclipse Ci fluorescence
microscope. Images were analysed with ImageJ software (v1.50b, USA). At least
five independent fields (>50 cells) per differentiation condition were used to
quantify the frequency of DAPI/FABP4-stained adipocytes or DAPI/osteocalcin-
stained osteoblasts.
Conditioned medium (CM) collection. ALL cell lines (Nalm-6, REH, RS4;11) and
three independent healthy human GCSF-mobilized peripheral blood (GMPB)
samples enriched for haematopoietic stem cells were cultured in RPMI and 10%
FBS for +72 h prior to supernatant collection. The cell viabilities prior to CM
collection were >85%. Supernatants were filtered and centrifuged to eliminate cells
and cell debris. Each CM was then aliquoted in a volume 5ml with the addition of
50 µl of adipogenic supplement before being frozen at −80 °C prior to use. No CM
controls were derived from RPMI, and 10% FBS cultured alone at +72 h was
treated similarly. Precollected CM and non-CM controls were then utilized to
induce adipogenic differentiation in P3 healthy MSCs, with medium changes as
detailed under “MSC differentiation”.
Oil red O staining. Oil red staining was performed by fixing cells with 4% PFA and
then incubating them with 60% isopropanol for 5 min prior to staining with 0.3%
oil red O (O0625, Sigma-Aldrich) in 60% isopropanol for 10 min at room tem-
perature (RT). Cells were washed with distilled water to remove excess dye and
counterstained with Mayer’s haematoxylin. Digital images were acquired using a
Nikon Eclipse Ci microscope. To quantify the staining intensity, oil red was eluted
in isopropanol, and absorbance was measured at a wavelength of 500 nm using a
FLUOstar Omega (BMG Labtech) microplate reader.
RNA sequencing. Total RNA was extracted from P4 ALL and healthy BM-MSCs
as well as Nalm-6 cells cocultured with 3T3-L1 preadipocytes or 3T3-L1 adipocytes
using the RNeasy mini kit (74104, Qiagen). RNA-seq was performed using
NextSeq™ 500 High Output Run (150 cycles) with 40-50 million reads and 150 bp
reads paired end. RNA-seq was performed in one technical run for the BM-MSC
samples and in two technical runs for the Nalm-6 cells. RNA-Seq reads were
aligned to the human genome (hg38) using Hisat2. Count files were generated by
mapping reads to the human genome (hg38) p5 using HTSeq. Differential
expression analysis was performed using Limma for BM-MSC RNA-seq and
DESeq2 in R for Nalm-6 cell RNA-seq. The p-values were further adjusted using
the Benjamini and Hocheberg procedure. Gene set enrichment analysis (GSEA)
was performed using GSEA software version 2.1.0 (Broad Institute) and the FGSEA
package in R (Broad Institute). Comparisons were made using curated (C2) gene
set collections from the Molecular Signatures Database (MSigDB). The Ggplot2
package in R was applied to visualize the results. Publicly available gene expression
datasets were used to compare gene expression profiles between mature human
osteoblasts and adipocytes (GSE945129). Heat map generation was performed
using individual probe sets. The array data have been deposited in the Gene
Expression Omnibus repository (GEO accession number GSE151802).
Cell lines. The human ALL cell lines Nalm-6 (CRL-3273), REH (CRL-8286) and
RS4;11 (CRL-1873) were purchased from ATCC (American Type Culture Col-
lection, Rockville, MD). ALL cell lines were cultured in RPMI 1640 medium
(2187534, Thermo Fisher Scientific) supplemented with 10% FBS, 100 units/ml
penicillin and 100 µg/ml streptomycin.
The murine fibroblast cell line 3T3-L1 (CL-173) was purchased from ATCC.
3T3-L1 cells were cultured in DMEM (41966029, Thermo Fisher Scientific)
supplemented with 10% FBS, 100 units/ml penicillin and 100 µg/ml streptomycin.
All cells were incubated at 37 °C and 5% CO2 under humidified conditions and
were routinely subjected to mycoplasma testing. Cell counts and viability
measurements were performed with the LUNA-FL™ Dual Fluorescence Cell
Counter (Logos Biosystems) using acridine orange/propidium iodide stain
(F23001, Logos Biosystems).
3T3-L1 adipocyte differentiation. 3T3-L1 preadipocytes were differentiated into
adipocytes according to standard methods with slight modifications59,60. Briefly,
two days post confluency (Day 0), DMEM (containing 10% FBS and antibiotics)
was supplemented with 0.5 mM 3-isobutyl-1-methylxanthine (I7018, Merck
KGaA), 0.25 μM dexamethasone (D2915, Merck KGaA), 2 μM rosiglitazone
(R2408, Merck KGaA) and 1 μg/ml insulin (I9278, Merck KGaA). After 48 h (Day
2), the medium was replaced with DMEM supplemented with 10% FBS, 1 μg/ml
insulin and antibiotics. The medium was subsequently changed to DMEM sup-
plemented with 10% FBS and antibiotics every 2 days until day 10, after which cells
were utilized for coculture experiments. The adipocyte conversion at this time was
reproducibly 100%, as demonstrated by adipocyte-specific FABP4 immuno-
fluorescence staining (Supplementary Fig. 3a).
ALL coculture experiments. Fully confluent stromal cultures were washed twice
with DPBS to remove differentiation media prior to adding ALL cell line sus-
pensions to RPMI medium containing 10% FBS and antibiotics. For 150 mm
culture dishes, the seeding density was 10 × 106 ALL cells in 30 ml media, and for
6-well plates, 0.5 × 106 ALL cells were seeded in 5 ml medium. The ratio of stromal
cells to ALL cells at the time of coculture was consistently 1:2. For assaying cell
number and cell cycle status, the full contents of cocultures, including stromal
elements, were collected by flushing the wells with DPBS prior to flow cytometry
analysis. To isolate ALL cells for reculture or RNA and protein extraction, cocul-
tures were subjected to light trypsinization with a 50% diluted trypsin/EDTA
solution for 1 min, followed by repeated washing with DPBS and gentle pipetting to
remove supernatant and avoid disturbance of the stromal monolayer. Purity
assessment of these supernatants by flow cytometry confirmed that stromal-cell
contamination was reproducibly <5%.
In specified experiments, coculture was performed in the presence of drugs
added 2 h after the coculture was set up corresponding to when ALL cells were fully
adherent to the adipocyte stroma. The added drugs were 20 µM SSO (sulfo-N-
succinimidyl oleate sodium; SML2148, Merck KGaA), 40 µM etomoxir (E1905,
Merck KGaA), 30 µM BMS309403 (5258, Tocris Bioscience) and GCN2ib (HY-
112654, Generon).
Flow cytometry. Flow cytometry was performed on an LSRFortessa™ flow cyt-
ometer (BD Biosciences). Data were analysed by FlowJo (version 10.1, Tree Star).
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Antibody staining was performed for 15 min in the dark. DAPI (D3571, Thermo
Fisher Scientific, 1:2000 in DPBS containing 2% FBS) was added prior to flow
cytometric analysis. Gates were set up to exclude doublets, nonviable cells (DAPI+,
or fixable viability dye+) and isotype-stained populations. Cell counts were
assessed using CountBright™ Absolute Counting Beads (C36950, Thermo Fisher
Scientific) on CD19+-gated populations.
Apoptotic cell death was assessed by dual staining with Annexin V-Alexa Fluor
647 (A23204, Thermo Fisher Scientific) and DAPI in CD19+-gated populations.
Cells were washed in Annexin V binding buffer (556454, BD Biosciences) and
stained with the B lineage ALL marker CD19-PE (clone 4G7; 345777, BD
Biosciences) and Annexin V Alexa Fluor 647 for 15 min, protected from light.
DAPI (1:2000 in Annexin V binding buffer) was added prior to flow cytometric
analysis.
Cell cycle assessment was performed by Ki67 and DAPI dual staining on
CD19+-gated populations. Cells were washed in DPBS containing 2% FBS and
stained with CD19-PE and Fixable Viability Dye eFluor™ 780 (65-0865-14, Thermo
Fisher Scientific) for 30 min at 4 °C. Cells were then fixed with ice-cold 70% ethanol
and kept at −20 °C. Subsequently, the samples were washed twice in DPBS
containing 2% FBS, stained with Ki67-FITC (556026, BD Biosciences) for 30 min,
and protected from light. DAPI (1:500 in DPBS containing 2% FBS) was added
prior to flow cytometric analysis. Gating of the different phases of the cell cycle was
determined by population analysis and isotype controls.
Intracellular lipid content was assessed by BODIPY™ 493/503 staining. Cells
were washed in DPBS and stained with BODIPY™ 493/503 (4,4-Difluoro-1,3,5,7,8-
Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene) (D3922, Thermo Fisher Scientific)
for 30 min at 37 °C. Subsequently, the samples were washed in DPBS, and DAPI
(1:2000 in DPBS) was added prior to flow cytometric analysis. BODIPY median
fluorescence intensity (MFI) was determined as a quantification of intracellular
lipid content.
For the assessment of the expression of the transmembrane fatty acid
transporter CD36, cells were washed in DPBS containing 2% FBS and stained with
CD36-APC (clone CB38; 550956, BD Biosciences) together with CD19-PE and
CD10-APC (clone HI10a 332777 BD Biosciences) for primary ALL samples or
CD34-APC (clone; 555824 BD Biosciences) together with CD33-PE (clone WM53;
555450, BD Biosciences) for AML samples. Gating strategies for flow cytometry are
summarized in Supplementary Fig. 6.
Osmium staining. Following euthanasia, murine tibiae were isolated, thoroughly
cleaned and fixed in 10% formalin at 4 °C for 48 h. Bones were decalcified for
14 days in 14% EDTA and washed in Sorensen’s phosphate buffer. Bones were then
stained for 48 h in 1% osmium tetroxide (Agar Scientific), washed in Sorensen’s
phosphate buffer and embedded in 1% agarose, forming layers of five tibiae
arranged in parallel in a 30 ml universal tube. Tubes of embedded tibiae were then
mounted in a Skyscan 1172 desktop micro-CT (Bruker microCT, Kontich). Sam-
ples were scanned through 360° using a step of 0.40° between exposures. A voxel
resolution of 12.05 μm was obtained in the scans using the following control
settings: 54 kV source voltage, 185 μA source current with an exposure time of
885 ms. A 0.5 mm aluminium filter and two-frame averaging were used to optimize
the scan. After scanning, the data were reconstructed using NRecon
v1.6.9.4 software (Bruker, Kontich, Belgium). The reconstruction thresholding
window was optimized to encapsulate the target image. Volumetric analysis was
performed using a CT Analyser v1.13.5.1 (Bruker microCT, Kontich).
Xenotransplantation experiments. All animal experiments were performed
under license PPL 70/8540 approved by the Home Office of the United Kingdom
and in accordance with institutional guidelines. Immunodeficient male (to avoid
gender-based variation in adiposity) NSG mice (NOD. Cg-Prkdcscid 112rgtm1Wjl/
SzJ) were obtained from Charles Rivers Laboratories. All mice were housed in
barrier accommodation in the Biological Services Unit at Queen Mary University
of London, Charterhouse Square. Thawed MNCs obtained from PB or BM from
ALL patients at diagnosis were resuspended in DPBS containing 10% FBS, and 5-
8 × 106 cells were administered intravenously into the tail vein of 7- to 10-week-old
nonirradiated mice. For Nalm-6 xenotransplantation, 0.5 × 106 cells were injected.
Engraftment of human leukaemic cells was examined every two weeks by intratibial
bone marrow sampling under anaesthesia (isoflurane) and postprocedure analgesia
(0.1 mg/kg vetergesic). Animal wellbeing and weight were regularly monitored, and
mice were euthanized when signs of disease-related symptoms developed, in
compliance with approved protocols or at leukaemia cell engraftment of >70%, as
determined by intratibial sampling. This threshold was approximately reached
6–8 weeks after tumour inoculation of primary ALL and 3-4 weeks with the Nalm-
6 ALL cell line. At sacrifice, bone marrow cells from the femur and the tail ver-
tebrae were isolated by mechanically crushing the bones with a mortar and pestle
in DPBS containing 2% FBS, followed by filtration through a 40 µM nylon mesh to
obtain a single-cell suspension. Following centrifugation, cell pellets were subjected
to red blood cell lysis using ammonium chloride (07850, STEMCELL Technolo-
gies) prior to flow cytometric analysis. Gonadal fat tissue was microdissected at
sacrifice, chopped and then digested with Liberase (5401119001, Roche) for 30 min
at 37 °C and processed as previously described39. Flow cytometric assessment of
primary human leukaemia engraftment was performed by CD19-PE and CD45-
FITC (clone 2D1; 345808, BD Biosciences) costaining of DAPI-viable cells or
CD19-PE and CD10-FITC (clone W8E7; 347503, BD Biosciences) costaining in the
case of Nalm-6 engraftment. Cell cycle analysis was performed on CD19+ -gated
populations as described under “Flow cytometry”. For Op-Puro analysis, 0.5 × 106
cells from femoral or tail bone marrow were incubated with 10 µM OP-Puro
reagent in RPMI medium containing 10% FBS for 20 min at 37 °C. OP-Puro
incorporation analysis was performed on CD19- and CD45+ -gated populations
as described under “O-propargyl-puromycin (OPP) labelling”.
Western blot analysis. Total cellular protein content was extracted in NuPAGE™
LDS Sample Buffer (NP0007, Thermo Fisher Scientific) containing 50 mM
dithiothreitol (NuPAGE™ Sample Reducing Agent; NP0009, Thermo Fisher Sci-
entific). Protein content was quantified using the Pierce™ BCA Protein Assay Kit
(23227, Thermo Fisher Scientific). Proteins were separated on NuPAGE™ 4–12%
Bis–Tris polyacrylamide gels (NP0335BOX, Thermo Fisher Scientific) and trans-
ferred onto 0.45 µM PVDF transfer membranes (88518, Thermo Fisher Scientific).
Membranes were blocked in Tris-buffered saline containing 0.1% TWEEN 20 and
5% BSA for 60 min at RT and then incubated with primary antibodies overnight at
4 °C. HRP-conjugated secondary antibodies were used at a 1:5000 dilution (anti-
rabbit 7074 and anti-mouse 7076, Cell Signaling Technology). Protein signals were
developed using SuperSignal™ West Pico PLUS Chemiluminescent Substrate
(34577, Thermo Fisher Scientific), and images were acquired using an Amersham
Imager 600 RGB (GE Healthcare). Densitometric analysis of immunoblots was
performed using ImageJ software.
Primary antibodies were purchased from Cell Signaling Technology: P21 (12D1,
2947), P27 (D69C12, 3686), phospho-P53 (Ser46, 2521), Cyclin D1 (E3P5S, 55506),
Cyclin E (HE12, 4129), phospho-Rb (Ser807/811, 8516), E2F-1 (3742), Phospho-
AMPK (Thr172, 2531), Phospho-mTOR (Ser2448; 2971), Phospho-S6 Ribosomal
Protein (Ser235/236; 2211), S6 Ribosomal Protein (5G10; 2217), Phospho-4EBP1
(Thr37/46; 2855), 4EBP1 (53H11; 9644), Phospho-eIF2α (Ser51; 9721), eIF2α
(9722) and ATF4 (D4B8; 11815). The anti α-Tubulin antibody was purchased from
Abcam (DM1A; ab7291). All primary antibodies were diluted 1:1000. In specified
experiments, ISRIB (200 nM, S7400, Selleckchem), PERK inhibitor (2 µM;
GSK2606414) or GCN2ib (5 µg/mL; HY-112654), 250 nM thapsigargin (1138,
Tocris Bioscience) or 1 µM Torin 1 (4247, Tocris Bioscience) prior to cell harvest
and lysate collection.
Lipidomics. Two technical replicates of ALL cells (3 × 106) were harvested from
3T3-L1 adipocytes or preadipocytes as described under “ALL coculture experi-
ments”. Cell pellets were washed twice in ice-cold DPBS, prepared by snap freezing
on dry ice and submitted to MS-Omics for lipidomic profiling. Lipids were
extracted from the samples using methanol, ultrapure water and methyl tert-butyl
ether. The organic phase used for lipid analysis was separated, transferred to
injection vials, dried under nitrogen flow and reconstituted in an isopropanol/
acetontril/water mixture. For quality control, a mixed pooled sample (QC sample)
was created by taking a small aliquot from each sample. This sample was analysed
at regular intervals throughout the sequence. Matrix effects were tested for quan-
tified compounds by spiking the QC sample at a minimum of two levels. Chro-
matographic separation was performed using a UPLC system (Vanquish, Thermo
Fisher Scientific) coupled with a high-resolution quadrupole-orbitrap mass spec-
trometer (Q Exactive™ HF Hybrid Quadrupole-Orbitrap, Thermo Fisher Scientific).
An electrospray ionization interface was used as the ionization source. Analysis was
performed in negative and positive ionization modes. A QC sample was analysed in
MS/MS mode for identification of compounds. UPLC was performed using a
slightly modified version of the protocol described by Isaas et al.61. Data were
processed using Compound Discoverer 3.0 (Thermo Fisher Scientific).
Oleic acid treatment. ALL cells at a concentration of 0.2 × 106 cells in 1 ml RPMI
medium (containing 10% FBS and antibiotics) were treated with 30 or 100 µM oleic
acid-albumin from bovine serum (O3008, Merck KGaA) for 24, 48 or 72 h.
Treatment with 0.3% bovine serum albumin (A7511, Merck KGaA) was used as a
control. An additional 1 ml of medium with the corresponding treatment was
supplemented after 24 h. Cell counts and viability measurements were performed
using acridine orange/propidium iodide staining.
Fatty acid translocation experiments using BODIPY. To examine directional
lipid transfer from adipocytes to ALL cells, 3T3-L1 adipocytes were incubated with
2 µg/ml BODIPY™ 558/568 C12 (4,4-Difluoro-5-(2-Thienyl)-4-Bora-3a,4a-Diaza-s-
Indacene-3-Dodecanoic Acid) (D3835, Thermo Fisher Scientific) for 4 h. The
adipocytes were washed with HBSS containing 0.2% fatty acid-free BSA to remove
extracellular fatty acids. Subsequently, ALL cell lines at a concentration of 0.2 × 106
cells/ml were cocultured with labelled 3T3-L1 adipocytes for 24 h before being
harvested, washed with HBSS containing 0.2% fatty acid-free BSA and analysed by
an Amnis® ImageStream®XMk II flow cytometer. Imagining was performed using
INSPIRE™ software.
Short hairpin RNA CD36 targeting. Knockdown of CD36 was achieved using
MISSION® shRNA lentiviral transduction particles cloned into the pLKO.1 lenti-
viral vector (CD36 shRNA: SHCLNV, nonmammalian shRNA control: SHC002V,
Merck KGaA). Sequences of transduction particles are listed in Supplementary
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Table 4. Cells were plated in 6-well plates (0.25 × 106 cells/well) and treated with
5 µg/ml polybrene for 15 min prior to transduction with the appropriate lentiviral
particles at a multiplicity of infection of 1. Cells were incubated with the particles
for 72 h, and then selection with 1.0 µg/ml puromycin was performed until use in
experiments. Cells were assayed for knockdown of CD36 by RT-qPCR.
Quantitative real-time PCR. RNA was extracted with a RNeasy Micro Kit (74004,
Qiagen) following the manufacturer’s protocol. RNA was quantified (total RNA,
18S rRNA and 28S rRNA), and RNA integrity was assessed using an RNA
ScreenTape (5067-5576, Agilent), RNA ScreenTape Sample Buffer (5067-5577,
Agilent) and the 4200 TapeStation System (G2991AA, Agilent). RNA was reverse
transcribed using the High-Capacity cDNA Reverse Transcription Kit (4368814,
Thermo Fisher Scientific). Quantitative real-time PCR was performed on a Touch™
Real-Time thermal cycler (CFX384, Bio-Rad) using SsoAdvanced™ Universal
SYBR® Green Supermix (1725271, Bio-Rad). Target primer sequences are listed in
Supplementary Table 5. β-Actin was used to normalize the RNA content. All
samples were analysed in triplicate and averaged.
Phosphoproteomic LC-MS/MS analysis. Nalm-6 cells were cocultured with 3T3-
L1 adipocytes or preadipocytes for 24 or 72 h in 150 mm culture dishes (see ALL
coculture experiments). Cells were isolated from coculture, and cell lysis and
trypsin digestion were performed following previously described protocols in urea
buffer (8 M urea in 20 mM in HEPES pH 8.0 supplemented with 1 mM Na3VO4,
1 mM NaF, 1 mM Na4P2O7 and 1 mM sodium β-glycerophosphate)40,62. Briefly,
proteins were quantified by BCA assay, and 250 µg of protein was reduced and
alkylated by sequential incubation with 10 mM dithiothreitol and 16.6 mM
iodoacetamyde. Urea was diluted to a concentration of 1.44M with 20 mM HEPES
(pH 8.0), and samples were incubated with trypsin beads [50% slurry of TLCK-
trypsin (20230, Thermo-Fisher Scientific)] on a thermoshaker overnight. Peptide
solutions were then desalted using 10 mg OASIS-HLB cartridges (Waters, Man-
chester, UK) and eluted with glycolic acid buffer (1 M glycolic acid, 50% ACN, 5%
TFA). Phosphopeptides were enriched as previously described using 50 µL of TiO2
beads [(50% slurry in 1% TFA) GL Sciences]40,62. For phosphopeptide recovery,
peptides were eluted in 5% NH4OH; dried peptide extracts were then dissolved in
0.1% TFA and analysed in an LC-MS/MS system. This consisted of a nanoflow
ultra-high pressure liquid chromatography system nanoflow ultimate 3000 RSL
nano (Dionex) coupled to a Q Exactive™ Plus Orbitrap™ Mass Spectrometer
(Thermo Fisher Scientific).
The LC system used mobile phases A (3% ACN: 0.1% FA) and B (100% ACN;
0.1% FA). Peptides were loaded onto a μ-precolumn (160454) and separated in an
analytical column (EASY-Spray; ES803). The gradient was 1% B for 5 min and 1%
B to 35% B for 60 min. Following elution, the column was washed with 85% B for
7 min and equilibrated with 3% B for 7 min at a flow rate of 0.25 µL/min. Peptides
were nebulized into the online connected Q-Exactive Plus system operating with a
2.1 s duty cycle. Acquisition of full-scan survey spectra (m/z 375–1500) with a
70,000 FWHM resolution was followed by data-dependent acquisition in which the
15 most intense ions were selected for HCD (higher energy collisional dissociation)
and MS/MS scanning (200–2000m/z) with a resolution of 17,500 FWHM. A 30 s
dynamic exclusion period was enabled with an exclusion list with a 10 ppm mass
window. The oxverall duty cycle generated chromatographic peaks of
approximately 30 s at the base, which allowed the construction of extracted ion
chromatograms (XICs) with at least ten data points.
Peptide identification and quantification. Mascot Distiller 2.7.1 was used to fit an
ideal isotopic distribution to the MS/MS data to maximize peptide identification,
and the Mascot Daemon 2.6 search engine was used to match peaks to peptides in
proteins present in the UniProt/SwissProt Database (human species). The process
was automated with Mascot Daemon 2.5.0, mass tolerance was set to ± 10 ppm,
and variable modifications phospho (ST), phospho (Y) gln→pyro-glu (N-term Q)
and oxidation (M) were included in the search. Carbamidomethyl (C) as fixed
modification. Trypsin was selected as the digestion enzyme, and 2 missed cleavages
were allowed. Sites of modification were reported when they had delta scores >10.
Peptide and subsequent protein quantification was achieved using in-house
developed Peak statistics calculator (PESCAL) software63. PESCAL constructs XICs
for each peptide identified with the MASCOT search engine. With each con-
structed XIC, peak heights could be calculated. These peptide peak heights were
then normalized to the sum of the intensities for each individual sample, and the
average fold change between conditions could be determined. Statistical sig-
nificance between conditions was considered significant when Student’s t tests
produced a p-value<0.05 following correction with Benjamini–Hochberg multiple
testing. Further data processing and analysis were conducted within Microsoft
Excel (2013) or R (v3.4.4-reshape2, ggplot2, gplots, readxl, Hmisc and ggrepel
packages). The Z-score was calculated based on the fold change, as previously
described40,64.
KSEA and gene ontology analysis. Kinase-substrate enrichment analysis (KSEA)
was performed as follows40; briefly, peptides differentially phosphorylated between
a set of samples (at non-adjusted p-value<0.05) were grouped into substrate sets
known to be phosphorylated by a specific kinase as annotated in the PhosphoSite,
Phospho. ELM, and PhosphoPOINT databases65–67. To infer enrichment of sub-
strate groups across sets of samples, the hypergeometric test was used, followed by
correction with Benjamini–Hochberg multiple testing. For gene ontology analysis,
proteins differentially phosphorylated between conditions (at non-adjusted p-
value<0.05) were grouped into gene ontologies (biological process) as annotated in
UniProt databases. To infer ontology enrichment across sets of samples, the
hypergeometric test was used, followed by correction with Benjamini–Hochberg
multiple testing.
O-propargyl-puromycin (OPP) labelling. The Click-iT™ Plus O-propargyl-
puromycin (OPP) Alexa Fluor™ 647 Protein Synthesis Assay Kit (C10458, Thermo
Fisher Scientific) was used to measure global protein synthesis. ALL cells were
isolated from their microenvironment as described under “ALL coculture experi-
ments” and immediately incubated with 10 µM OP-Puro for 20 min at 37 °C in
ALL cell line-specific media, RPMI containing 10% FBS and antibiotics. In specific
experiments, 10 μg/ml cycloheximide (CHX; C4859, Merck KGaA) was added
10 min prior to OP-Puro to block protein translation, thereby serving as a positive
control. Cells were subsequently washed in DPBS containing 2% FBS and stained
with CD19-PE. A further wash was performed prior to fixation with the Fixation/
Permeabilization Solution Kit (554714, BD Biosciences). Incubation with the Click-
iT® Plus OPP reaction cocktail provided in the kit containing Alexa Fluor® 647
picolyl azide for 30 min led to the “click” reaction and azide-alkyne cycloaddition.
Additional DPBS containing 2% FBS washes followed prior to addition of DAPI
(1:2000 in DPBS containing 2% FBS) and flow cytometric analysis. OP-Puro MFI
was measured to quantify protein synthesis. To assess the effect of proteasome
activity on OP-Puro incorporation, cells were treated with 10 µM MG-132 (M7449,
Merck KGaA) for 2 h. At the final 20 min of incubation, 10 µM OP-Puro reagent
was added.
For the rescue experiment, ALL cells were cocultured with either 3T3-L1
adipocytes or preadipocytes for 24 h, and then 0.5 × 106 cells were extracted from
their microenvironment, washed and recultured in fresh RPMI medium for an
additional 48 h. ALL cells (0.5 × 106) were plated in parallel as a monoculture
control. Cell number and OP-puro incorporation at 24 and 48 h following
microenvironmental extraction were assessed.
In vitro Transwell experiments. Transwell assays were performed as previously
described68. In brief, 0.5 × 106 Nalm-6 cells resuspended in 5 ml RPMI containing
10% FBS and antibiotics were added to the upper chamber, with confluent 3T3-L1
adipocytes or preadipocytes placed in the bottom chamber of a 24 mm Corning®
Transwell system with 0.4 μm pore polyester membrane inserts (CLS3450, Corning
NY Merck KGaA). After +24 h, the number of CD19 +Nalm-6 cells in the upper
chamber and OP-puro incorporation in CD19 +Nalm-6 cells were quantified as
described under “Flow cytometry” and “O-propargyl-puromycin (OPP) labelling”.
Adipocyte secretome experiment. 3T3-L1 adipocytes and preadipocytes were
cultured for 72 h in 100% confluent 100 mm cell culture dishes, and culture
medium was collected and stored at −20 °C until use. Nalm-6 cells were adapted to
DMEM for 72 h prior to seeding at a concentration of 2 × 106 cells in 4 ml adi-
pocyte- or preadipocyte-conditioned medium, following which cell number (using
CountBright™ Absolute Counting Beads) and protein translation were assessed as
described under “Flow Cytometry” and “O-propargyl-puromycin (OPP) labelling”.
Stress experiments. Nalm-6 cells were isolated from monoculture or from 3T3-L1
adipocyte coculture at 48 h, washed twice in DPBS and resuspended in ALL cell
line-specific media at equivalent densities of 105 cells/100 µl per well in black
NuncTM F96 MicroWellTM plates (137101, Thermo Fisher Scientific). Subse-
quently, various treatments were added (final concentrations): 0.1 µg/ml cytar-
abine, 0.01 µg/ml vincristine, 0.1 µg/ml daunorubicin or a combination of the three
chemotherapeutic agents with 100 µM hydrogen peroxide (H1009, Merck KGaA).
Nutritional deprivation was induced by replating cells without the addition of FBS.
In specified experiments, GCN2ib (5 µg/mL; HY-112654, Selleckchem) was added
along with the indicated cellular stressor(s). At the indicated times, cell viability
was assessed using the CellTiter-Glo® Luminescent Cell Viability Assay according
to the manufacturers’ instructions. Luminescence was recorded using a FLUOstar
Omega microplate reader. Luminescence signals were normalized to untreated
controls at the respective timepoints. For confirmation, untreated controls were
assessed at +4 h following microenvironmental extraction to confirm the persis-
tence of translation arrest using O-propargyl-puromycin (OPP) labelling (S5a).
Pulsed SILAC-based proteomic analysis. Nalm-6 cells were cocultured with 3T3-
L1 adipocytes or preadipocytes for 24 or 48 h in 150 mm culture dishes (see ALL
coculture experiments). Subsequently, the cells were pulsed with either ‘heavily’ (H)
or ‘moderately’ (M) isotope-labelled amino acids for +4 h. Cells were then isolated
from coculture, lysed in 2% SDS and 50 mM Tris-HCl pH 7.5, sonicated and
balanced following protein quantification. Equal amounts of the corresponding
H&M lysates were then mixed together and subsequently trypsin digested using the
filter-aided sample preparation (FASP) method69. Pooled peptides were then
fractionated into seven peptide fractions using the Pierce™ High pH Reversed-
Phase Peptide Fractionation Kit (84868, Thermo Fisher Scientific) according to the
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manufacturers’ instructions. Different fractions were then lyophilized and resus-
pended in 0.1% TFA and 2% acetonitrile prior to analysis on a Q Exactive™ Plus
Orbitrap™ Mass Spectrometer coupled with a nanoflow ultimate 3000 RSL nano
HPLC platform (Thermo Fisher Scientific). Briefly, samples were resolved at a flow
rate of 250 nl/min on an Easy-Spray 50 cm × 75 μm RSLC C18 column (Thermo
Fisher Scientific) using a 123 min gradient of 3% to 35% of buffer B (0.1% formic
acid in acetonitrile) against buffer A (0.1% formic acid in water), and the separated
samples were infused into the mass spectrometer by electrospray. The spray voltage
was set at 1.95 kV, and the capillary temperature was 255 °C. The mass spectro-
meter was operated in data-dependent positive mode with 1 MS scan followed by
15 MS/MS scans (top 15 methods). The scans were acquired in the mass analyser at
375–1500m/z range, with a resolution of 70,000 for the MS scans and 17,500 for
the MS/MS scans. Fragmented peaks were dynamically excluded for 30 sec. Max-
Quant (version 1.6.3.3) software was used for the database search and SILAC
quantification of mass spectrometry raw files70. The search was performed against
a FASTA file of the human proteome extracted from UniProt.org. A precursor
mass tolerance of 4.5 ppm and a fragment mass tolerance of 20 ppm were applied.
Methionine oxidation and N-terminal acetylation were included as variable
modifications, while carbamidomethylation was applied as a fixed modification.
Two trypsin miscleavages were allowed, and the minimum peptide length was set
to seven amino acids. All other MaxQuant parameters apart from the ratio count
cut-off (set at 1) were kept as defaults. All raw files were searched together with the
match between runs option set as enabled and re-quantify option as disabled. All
downstream data analyses were performed with Perseus (version 1.5.5.3)71 using
the MaxQuant ProteinGroups.txt output file. Briefly, protein H/M ratio values were
converted to Log2 scale. Reverse (decoy) hits, potential contaminants, and proteins
identified only by modified peptides were filtered out. Proteins were also filtered to
have at least one valid H/M SILAC value. Fisher’s exact test was performed with
Perseus using a Benjamini–Hochberg FDR of 5%.
Statistical analysis. Data are presented as the mean with standard error of the
mean or as the median with interquartile ranges. Results with a p-value<0.05 were
considered statistically significant. Statistical analyses were performed using
GraphPad Prism 8 software (GraphPad, San Diego, CA). All data were subjected to
normality testing prior to statistical assessment with software-recommended tests.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability statement
The datasets generated during the current study have been deposited to the Gene
Expression Omnibus repository via GEO accession number GSE151802. All raw mass
spectrometry files reported in this paper have been deposited to the ProteomeXchange
Consortium via, PXD019186 and PXD019369. All source data supporting the findings of
this study are available within the article and its supplementary information files and
from the corresponding author upon reasonable request. Source data are provided with
this paper.
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